Literature DB >> 12705497

Blood mononuclear cell coenzyme Q10 concentration and mitochondrial respiratory chain succinate cytochrome-c reductase activity in phenylketonuric patients.

I P Hargreaves1, S J R Heales, A Briddon, J M Land, P J Lee.   

Abstract

Coenzyme Q10 (CoQ10) serves as an electron carrier within the mitochondrial respiratory chain (MRC), where it is integrally involved in oxidative phosphorylation and consequently ATP production. It has recently been suggested that phenylketonuria (PKU) patients may be susceptible to a CoQ10 deficiency as a consequence of their phenylalanine-restricted diet, which avoids foods rich in CoQ10 and its precursors. Furthermore, the high phenylalanine level in PKU patients not on dietary restriction may also result in impaired endogenous CoQ10 production, as previous studies have suggested an inhibitory effect of phenylalanine on HMG-CoA reductase, the rate-controlling enzyme in CoQ10 biosynthesis. We investigated the effect of both dietary restriction and elevated plasma phenylalanine concentration on blood mononuclear cell CoQ10 concentration and the activity of MRC complex II + III (succinate:cytochrome-c reductase; an enzyme that relies on endogenous CoQ10) in a PKU patient population. The concentrations of CoQ10 and MRC complex II + III activity were not found to be significantly different between the PKU patients on dietary restriction, PKU patients off dietary restriction and the control group, although plasma phenylalanine levels were markedly different. The results from this investigation suggest that dietary restriction and the elevated plasma phenylalanine levels of PKU patients do not effect mononuclear cell CoQ10 concentration and consequently the activity of complex II + III of the MRC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12705497     DOI: 10.1023/a:1022881231253

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  17 in total

1.  A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency.

Authors:  E Boitier; F Degoul; I Desguerre; C Charpentier; D François; G Ponsot; M Diry; P Rustin; C Marsac
Journal:  J Neurol Sci       Date:  1998       Impact factor: 3.181

2.  Decreased serum ubiquinone-10 concentrations in phenylketonuria.

Authors:  R Artuch; M A Vilaseca; J Moreno; N Lambruschini; F J Cambra; J Campistol
Journal:  Am J Clin Nutr       Date:  1999-11       Impact factor: 7.045

Review 3.  Biosynthesis of ubiquinone.

Authors:  R E Olson; H Rudney
Journal:  Vitam Horm       Date:  1983       Impact factor: 3.421

4.  Plasma phenylalanine is associated with decreased serum ubiquinone-10 concentrations in phenylketonuria.

Authors:  R Artuch; C Colomé; M A Vilaseca; C Sierra; F J Cambra; N Lambruschini; J Campistol
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

5.  Ubiquinone-10 content in lymphocytes of phenylketonuric patients.

Authors:  Catrina Colomé; Rafael Artuch; Maria A Vilaseca; Cristina Sierra; Nuria Brandi; Francisco J Cambra; Nilo Lambruschini; Jaume Campistol
Journal:  Clin Biochem       Date:  2002-02       Impact factor: 3.281

6.  Serum and muscle tissue ubiquinone levels in healthy subjects.

Authors:  R Laaksonen; A Riihimäki; J Laitila; K Mårtensson; M J Tikkanen; J J Himberg
Journal:  J Lab Clin Med       Date:  1995-04

7.  Brain MRI changes in phenylketonuria. Associations with dietary status.

Authors:  A J Thompson; S Tillotson; I Smith; B Kendall; S G Moore; D P Brenton
Journal:  Brain       Date:  1993-08       Impact factor: 13.501

8.  Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy.

Authors:  S Ogasahara; A G Engel; D Frens; D Mack
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

9.  In vivo measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy.

Authors:  E J Novotny; M J Avison; N Herschkowitz; O A Petroff; J W Prichard; M R Seashore; D L Rothman
Journal:  Pediatr Res       Date:  1995-02       Impact factor: 3.756

10.  Neurological deterioration in young adults with phenylketonuria.

Authors:  A J Thompson; I Smith; D Brenton; B D Youl; G Rylance; D C Davidson; B Kendall; A J Lees
Journal:  Lancet       Date:  1990-09-08       Impact factor: 79.321

View more
  10 in total

1.  Coenzyme-Q(10) concentration in human phenylketonuria.

Authors:  R Artuch; M A Vilaseca; N Lambruschini; J Campistol
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 2.  The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications.

Authors:  Iain P Hargreaves; Andrew J Duncan; Simon J R Heales; John M Land
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  Oxidative stress in phenylketonuria: future directions.

Authors:  Júlio César Rocha; Maria João Martins
Journal:  J Inherit Metab Dis       Date:  2011-11-25       Impact factor: 4.982

Review 4.  Phenylketonuria Pathophysiology: on the Role of Metabolic Alterations.

Authors:  Patrícia Fernanda Schuck; Fernanda Malgarin; José Henrique Cararo; Fabiola Cardoso; Emilio Luiz Streck; Gustavo Costa Ferreira
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

5.  A Multiplatform Metabolomics Approach to Characterize Plasma Levels of Phenylalanine and Tyrosine in Phenylketonuria.

Authors:  H Blasco; C Veyrat-Durebex; M Bertrand; F Patin; F Labarthe; H Henique; P Emond; C R Andres; C Antar; C Landon; L Nadal-Desbarats; F Maillot
Journal:  JIMD Rep       Date:  2016-06-15

6.  Assessment of mitochondrial respiratory chain function in hyperphenylalaninaemia.

Authors:  N Kyprianou; E Murphy; P Lee; I Hargreaves
Journal:  J Inherit Metab Dis       Date:  2009-03-13       Impact factor: 4.982

7.  Coenzyme q10 ameliorates ultraviolet B irradiation induced cell death through inhibition of mitochondrial intrinsic cell death pathway.

Authors:  Li Jing; Santosh Kumari; Natalia Mendelev; P Andy Li
Journal:  Int J Mol Sci       Date:  2011-11-24       Impact factor: 5.923

8.  A Clinical, Neuropathological and Genetic Study of Homozygous A467T POLG-Related Mitochondrial Disease.

Authors:  Sanjeev Rajakulendran; Robert D S Pitceathly; Jan-Willem Taanman; Harry Costello; Mary G Sweeney; Cathy E Woodward; Zane Jaunmuktane; Janice L Holton; Thomas S Jacques; Brian N Harding; Carl Fratter; Michael G Hanna; Shamima Rahman
Journal:  PLoS One       Date:  2016-01-06       Impact factor: 3.240

Review 9.  Evidence of Oxidative Stress and Secondary Mitochondrial Dysfunction in Metabolic and Non-Metabolic Disorders.

Authors:  Karolina M Stepien; Robert Heaton; Scott Rankin; Alex Murphy; James Bentley; Darren Sexton; Iain P Hargreaves
Journal:  J Clin Med       Date:  2017-07-19       Impact factor: 4.241

10.  Mitochondrial dysfunction is a key pathological driver of early stage Parkinson's.

Authors:  Christina E Toomey; Wendy E Heywood; Kevin Mills; Sonia Gandhi; James R Evans; Joanne Lachica; Sarah N Pressey; Sandrine C Foti; Mesfer Al Shahrani; Karishma D'Sa; Iain P Hargreaves; Simon Heales; Michael Orford; Claire Troakes; Johannes Attems; Ellen Gelpi; Miklos Palkovits; Tammaryn Lashley; Steve M Gentleman; Tamas Revesz
Journal:  Acta Neuropathol Commun       Date:  2022-09-08       Impact factor: 7.578

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.